Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Daniel McAleese

Trial Manager

Following completion of a MSc in Public Health from the University of Bristol, I joined the Oncology Clinical Trials Office (OCTO) in December 2017 as a Clinical Trial Support Officer. After spending a year at an international CRO in 2019 gaining experience on industry-led research, I returned to OCTO working in the Pharmacovigilance Team across all safety reporting trials. 

In September 2021 I started as a Trial Manager working on IPI-GLIO, CEeDD and IMAGO. 

IPI-GLIO: A Phase II, Open Label, Randomised Study of Ipilimumab with Temozolomide versus Temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. 

CEeDD: A First-in Human Clinical Investigation of Cavitation Enhanced Drug Delivery to Solid Tumours by co-Administration of the Sonosensitive Particles and Application of Extracorporeal Ultrasound in Patients with Colorectal Metastases to the Liver 

IMAGO: A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI